Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Pandit
 
CTRI/2020/06/026087
RCTpegylated interferon-α2bstandard of careCOVID-19 mild to moderatesome concern
20/20 suggested
  • inconclusive 7.8-fold increase in clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 9.2-fold increase in viral clearance by day 14 with a moderate degree of certainty due to some concern in risk of bias
Shashi Bhushan
 
CTRI/2020/12/029855
RCTpegylated interferon-α2bstandard of careCOVID-19 mild to moderatesome concern
120/130 safety concern
  • suggested 91 % increase in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 1.8-fold increase in viral clearance ,viral clearance by day 7 with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 100 % decrease in viral clearance by day 14 with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).